TSH Levels: Evidence-Based Ways to Improve Your Number

What TSH Actually Measures (and Why It Matters More for Women)

TSH is not a thyroid hormone itself. It is secreted by the pituitary gland and tells the thyroid how hard to work. When thyroid output is low, the pituitary pushes TSH up. When thyroid output is high, TSH falls. That inverse relationship makes it the most sensitive early signal of thyroid dysfunction, often rising or falling months before free T4 leaves its reference range.

Women develop thyroid disorders at five to eight times the rate of men, driven largely by autoimmune susceptibility tied to X-chromosome gene dosage and the immunomodulatory effects of estrogen and progesterone. Hashimoto's thyroiditis, which pushes TSH up, is the most common autoimmune disease in women. Graves' disease, which suppresses TSH, clusters in the reproductive years and can flare postpartum.

Because so many thyroid symptoms overlap with hormonal shifts at different life stages, an abnormal TSH is often the first concrete clue that something other than "just perimenopause" or "just stress" is driving fatigue, weight gain, or irregular periods.

How the Menstrual Cycle Affects TSH

TSH does not follow a predictable menstrual-cycle pattern the way LH or estrogen does, but estrogen affects thyroid-binding globulin (TBG), the protein that carries thyroid hormone in the blood. Higher estrogen, as seen in the follicular phase or in women taking oral contraceptives, raises TBG. That can make total T4 look high while free T4 stays normal. TSH itself stays relatively stable across the cycle in euthyroid women, so a TSH drawn at any cycle day is valid for screening.

TSH and PCOS

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of autoimmune thyroid disease. A 2015 meta-analysis in the European Journal of Endocrinology found subclinical hypothyroidism in roughly 26% of women with PCOS compared with about 8% of controls. If you have PCOS and are dealing with unexplained fatigue, weight resistance, or worsening insulin resistance, a TSH is a low-cost test worth ordering.

What Is a Normal TSH Range?

The Endocrine Society and the American Association of Clinical Endocrinology (AACE) place the standard adult reference range at approximately 0.5 to 4.5 mIU/L, though individual laboratory cutoffs vary slightly. The American Thyroid Association (ATA) acknowledges ongoing debate about whether the upper limit should be lowered to 2.5 mIU/L to catch earlier dysfunction, but no major guideline has adopted that change universally for the general population.

Life-Stage Adjustments to the Reference Range

| Life Stage | TSH Target / Range | Source | |---|---|---| | Reproductive-age, non-pregnant | 0.5 to 4.5 mIU/L | Endocrine Society | | Trying to conceive | 0.5 to 2.5 mIU/L | ATA/ACOG | | First trimester | <2.5 mIU/L | ATA 2017 | | Second trimester | <3.0 mIU/L | ATA 2017 | | Third trimester | <3.5 mIU/L | ATA 2017 | | Postpartum (non-lactating) | 0.5 to 4.5 mIU/L | Endocrine Society | | Perimenopause / post-menopause | 0.5 to 4.5 mIU/L (same range) | Endocrine Society | | Age >70 | Up to 6.0 mIU/L may be acceptable | ATA |

The tighter pregnancy targets exist because even subclinical hypothyroidism in the first trimester is associated with increased risk of miscarriage and impaired fetal neurodevelopment.

A Note on "Optimal" vs. "Normal"

Some functional medicine sources promote a narrow optimal range of 1.0 to 2.0 mIU/L. There is no randomized trial evidence that treating a TSH of 3.8 in a symptom-free woman to bring it to 1.5 improves outcomes. Targeting a specific number in the absence of symptoms and a confirmed diagnosis is not supported by the USPSTF, which does not recommend screening asymptomatic adults for thyroid dysfunction.

What a High TSH Means and How to Lower It

A TSH above your range means the pituitary is working overtime to stimulate an underperforming thyroid. The clinical term is hypothyroidism (overt) or subclinical hypothyroidism (when TSH is elevated but free T4 is still normal).

Causes in Women

• Hashimoto's thyroiditis: autoimmune destruction of thyroid tissue; confirmed by elevated TPO antibodies
• Post-radioactive iodine or thyroid surgery: permanent reduction in thyroid tissue
• Postpartum thyroiditis: affects 5 to 10% of postpartum women; often transient but can become permanent
• Iodine deficiency: still a cause globally; rare in iodine-replete countries
• Medication-induced: lithium, amiodarone, interferon-alpha, certain checkpoint inhibitors

Evidence-Based Strategies to Lower a High TSH

Levothyroxine (T4 replacement): the primary intervention. For overt hypothyroidism (high TSH plus low free T4), levothyroxine is the standard of care per both the Endocrine Society and AACE. Starting dose in healthy adults is typically 1.6 mcg/kg/day. Women with cardiac disease or older patients start lower, around 25 to 50 mcg/day with gradual uptitration.

For subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4), the 2019 European Thyroid Journal guideline suggests treatment is most clearly beneficial when TSH exceeds 10 mIU/L, when the woman is symptomatic, or when she is pregnant or trying to conceive. Watchful waiting with repeat testing in 3 to 6 months is appropriate for many women in the 4.5 to 10 range.

Selenium supplementation in Hashimoto's. The thyroid contains the highest selenium concentration of any organ. In a 2002 randomized controlled trial by Gärtner et al. In the Journal of Clinical Endocrinology and Metabolism, 200 mcg/day of selenomethionine reduced TPO antibody titers by approximately 49% compared with placebo over 3 months. A 2018 Cochrane review found selenium modestly lowered antibodies but noted that data on patient-centered outcomes like quality of life remain limited. A reasonable approach is to check serum selenium before supplementing, and to stay below 400 mcg/day to avoid toxicity.

Iodine: enough but not too much. Severe iodine deficiency raises TSH. Correcting deficiency (through iodized salt or a multivitamin containing 150 mcg iodine) can normalize TSH in true deficiency states. Excess iodine, however, can worsen autoimmune thyroid disease through the Wolff-Chaikoff effect. Women with Hashimoto's should avoid high-dose iodine supplements (above 500 mcg/day) without medical supervision.

Gluten and thyroid antibodies. Women with Hashimoto's have a four-fold higher prevalence of celiac disease than the general population. In those with confirmed celiac, a strict gluten-free diet lowers intestinal inflammation and may reduce antibody load. For women without celiac or non-celiac gluten sensitivity, the evidence for gluten avoidance improving TSH is thin and should not replace medical treatment.

Vitamin D. Low vitamin D is associated with higher TPO antibody titers in observational data, but no well-powered interventional trial has shown that correcting vitamin D deficiency directly lowers TSH in hypothyroid women. Correcting deficiency (to a 25-OH vitamin D of at least 30 ng/mL) is still worth doing for bone and immune health.

The WomanRx TSH Improvement Framework for High TSH: Think in three tiers. Tier 1 is confirming the diagnosis (repeat TSH plus free T4 and TPO antibodies). Tier 2 is addressing the cause (medication if indicated, correcting iodine or selenium deficiency, treating celiac if present). Tier 3 is monitoring (TSH recheck 6 to 8 weeks after any dose change, then annually once stable). Lifestyle changes sit alongside Tier 2, not instead of Tier 1.

What a Low TSH Means and How to Raise It

A TSH below the reference range signals that the pituitary is pulling back because thyroid hormone levels are too high. The clinical diagnoses are hyperthyroidism (overt) or subclinical hyperthyroidism (low TSH, normal free T4 and free T3).

Causes in Women

• Graves' disease: TSH-receptor antibody-driven; peaks in women aged 30 to 50
• Toxic nodular goiter or toxic adenoma: autonomous nodule producing excess hormone
• Postpartum thyroiditis (hyperthyroid phase): occurs in the first 1 to 6 months postpartum
• Overtreatment with levothyroxine: the most preventable cause; check your dose
• Excess iodine or iodine-containing drugs: amiodarone is a major offender
• TSH-secreting pituitary adenoma: rare

Evidence-Based Strategies to Raise a Low TSH

Adjusting levothyroxine dose is the fix if over-replacement is the cause. A TSH below 0.1 mIU/L on levothyroxine is associated with increased risk of atrial fibrillation and accelerated bone loss, particularly concerning for perimenopausal women already losing bone. A simple dose reduction, guided by recheck TSH in 6 weeks, usually resolves this.

Antithyroid medications for Graves' disease. Methimazole is first-line in the United States for most non-pregnant adults; it inhibits thyroid hormone synthesis. Propylthiouracil (PTU) is preferred in the first trimester of pregnancy because methimazole carries a small risk of embryopathy. The ATA 2016 guideline on hyperthyroidism recommends antithyroid drug therapy, radioactive iodine, or thyroidectomy based on individual circumstances, disease severity, and reproductive plans.

Radioactive iodine (RAI) and thyroidectomy are definitive treatments. Both result in hypothyroidism requiring lifelong levothyroxine, which then requires TSH monitoring to avoid over-replacement.

Watchful waiting for subclinical hyperthyroidism. For a mildly suppressed TSH (0.1 to 0.4 mIU/L) with normal free T4 and T3 and no symptoms, many guidelines favor monitoring over immediate treatment, particularly in younger women. The 2019 European Thyroid Journal guideline recommends treatment when TSH is persistently <0.1 mIU/L or when the woman has cardiac risk factors or osteoporosis.

Selenium and antioxidants in Graves' orbitopathy. A 2011 NEJM trial by Marcocci et al. Showed 200 mcg/day of selenium for 6 months significantly improved mild Graves' orbitopathy compared with placebo, with no effect on thyroid function itself. This targets the eye disease, not TSH directly.

TSH Across Your Reproductive Life

Trying to Conceive

The ATA recommends a preconception TSH target of 0.5 to 2.5 mIU/L for women with known hypothyroidism who are actively trying to conceive. If your TSH is above 2.5 and you have TPO antibodies or a history of miscarriage, most reproductive endocrinologists will start or increase levothyroxine before a positive pregnancy test.

Pregnancy and Lactation

Pregnancy profoundly changes thyroid physiology. HCG, which surges in the first trimester, stimulates TSH receptors and physiologically suppresses TSH, sometimes to undetectable levels in weeks 8 to 12. TBG doubles by mid-pregnancy, raising total T4 requirements. Women on levothyroxine typically need a 25 to 50% dose increase starting as soon as pregnancy is confirmed, often operationalized as taking two extra doses per week immediately.

Levothyroxine is safe in pregnancy. It is the same hormone your thyroid produces. Untreated hypothyroidism in pregnancy carries real risks: increased rates of preeclampsia, preterm birth, and lower IQ scores in offspring, as documented in the CATS trial published in NEJM in 2012. That trial found that screening and treating subclinical hypothyroidism did not improve child IQ at age 3, but the debate about timing of treatment (very early first trimester) continues.

TSH should be rechecked every 4 weeks in the first half of pregnancy and at least once in the second half in women with known thyroid disease per ACOG Practice Bulletin 223.

Lactation: Levothyroxine passes into breast milk in tiny amounts and is considered safe by ACOG and the Endocrine Society. Methimazole at doses up to 20 to 30 mg/day is also considered compatible with breastfeeding per LactMed. PTU is preferred by some clinicians in the early postpartum period but carries a rare risk of hepatotoxicity.

Postpartum thyroiditis deserves specific mention. It follows a classic triphasic pattern: hyperthyroid phase (1 to 4 months postpartum), hypothyroid phase (4 to 8 months), then return to normal in most women. However, up to 25% develop permanent hypothyroidism within 7 years. If you had postpartum thyroiditis after one pregnancy, your risk of recurrence in the next is approximately 70%.

Perimenopause and Post-Menopause

The TSH reference range does not change at menopause, but the symptom overlap is extraordinary. Hot flashes, brain fog, fatigue, weight gain, irregular periods, and sleep disruption are shared between thyroid dysfunction and the menopausal transition. A TSH should be part of the initial workup before attributing these symptoms entirely to perimenopause.

Postmenopausal women on levothyroxine who are also taking oral estrogen therapy may need a higher levothyroxine dose because oral estrogen raises TBG, increasing hormone binding and reducing free T4. Transdermal estrogen has a much smaller effect on TBG and usually does not require a levothyroxine dose change. This is a clinically significant and underappreciated pharmacokinetic interaction documented in the Endocrine Society guidelines.

Bone health is the other major concern. Suppressed TSH (below 0.1 mIU/L) from overtreatment or Graves' disease accelerates bone resorption. Postmenopausal women without estrogen protection are at highest risk. If your TSH has been persistently low, ask your provider to check bone density.

Medications and Supplements That Interfere with TSH Testing or Treatment

Several common agents alter TSH results or block levothyroxine absorption, and women are disproportionately affected because they use these agents more often.

| Agent | Effect on TSH or Thyroid | Timing Guidance | |---|---|---| | Calcium carbonate | Blocks levothyroxine absorption | Take levothyroxine 4 hours apart | | Iron supplements | Blocks levothyroxine absorption | Take levothyroxine 4 hours apart | | Magnesium | Minor absorption interference | Separate by 2 to 4 hours | | Proton pump inhibitors | Reduce gastric acid, impair T4 dissolution | Take levothyroxine on empty stomach | | Biotin (>5 mg/day) | False-low TSH on immunoassay | Stop biotin 48 to 72 hours before blood draw | | Oral estrogen | Raises TBG, may raise levothyroxine requirement | Monitor TSH 6 to 8 weeks after starting | | Amiodarone | Raises or lowers TSH unpredictably | Endocrinology co-management recommended |

Biotin interference deserves emphasis for women. Many women take high-dose biotin (5 to 10 mg/day) for hair loss or nail growth. Biotin at these doses falsely lowers TSH on biotin-streptavidin immunoassays, creating a spurious picture of hyperthyroidism. Stop biotin for at least 48 to 72 hours before any thyroid panel.

Who Should Actively Work to Improve Their TSH

Not every woman with an abnormal TSH number needs aggressive intervention. Here is a practical guide by situation.

Clear Candidates for Treatment

• Overt hypothyroidism (high TSH plus low free T4), any life stage
• Subclinical hypothyroidism plus pregnancy or trying to conceive
• Subclinical hypothyroidism plus TPO antibodies plus symptoms
• Overt hyperthyroidism (low TSH plus elevated free T4 or T3), any life stage
• Suppressed TSH in a postmenopausal woman with low bone density

Reasonable to Monitor Without Immediate Treatment

• Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) in a symptom-free, non-pregnant woman
• Mildly suppressed TSH (0.1 to 0.4 mIU/L) without symptoms or cardiac risk factors
• Postpartum thyroiditis in the hyperthyroid phase (usually self-limiting)
• Single abnormal TSH in a woman with a major intercurrent illness (TSH can shift with any acute illness)

Not Candidates for Intervention

• A TSH within the normal range in an asymptomatic woman who had the test done as a "wellness check"
• A TSH of 3.5 in a woman whose symptoms are fully explained by another condition
• Treating a "suboptimal" TSH based on functional medicine targets without a confirmed diagnosis

Monitoring: How Often Should You Check TSH

Once stable on levothyroxine, the Endocrine Society recommends annual TSH checks. Recheck TSH 6 to 8 weeks after any dose change. During pregnancy, recheck every 4 weeks through week 20, then at least once in the third trimester. After delivery, women who increased their dose in pregnancy should recheck TSH 6 weeks postpartum, because requirements usually fall back to pre-pregnancy levels within weeks of delivery.

Conditions that call for an earlier-than-annual recheck include starting or stopping oral estrogen, significant weight change (greater than 10% body weight), starting amiodarone or lithium, or a new diagnosis of malabsorption (celiac, bariatric surgery).

Evidence Gaps: What We Do Not Know Yet

Women have historically been under-represented in thyroid intervention trials, even though women bear the majority of thyroid disease burden. Several important questions remain without definitive answers from female-predominant trial populations:

The TRUST trial (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism) enrolled adults over 65 and found that levothyroxine produced no benefit over placebo on quality of life or fatigue scores at 1 year. About half the participants were women, but sex-stratified outcomes were not a prespecified endpoint, so we cannot say definitively whether older women respond differently from older men.

The optimal TSH target during IVF cycles in euthyroid women is debated. Observational data suggest TSH above 2.5 may reduce IVF success rates, but no randomized trial has confirmed that lowering TSH in euthyroid women improves live birth rates.

The role of T3 combination therapy (levothyroxine plus liothyronine) versus levothyroxine alone in symptomatic women who remain unwell on T4 monotherapy is an active research area. The 2019 American Thyroid Association task force statement acknowledges patient heterogeneity but does not yet endorse routine combination therapy.